Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$10.02
+1.1%
$10.62
$9.22
$14.63
$1.17B1.242.08 million shs1.04 million shs
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$3.36
$0.00
$2.47
$5.98
$344.00M2.351.69 million shs2.60 million shs
MannKind Corporation stock logo
MNKD
MannKind
$5.54
-3.6%
$3.90
$3.38
$7.63
$1.70B1.022.65 million shs6.03 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.45
-1.4%
$7.45
$5.01
$15.22
$1.21B2.686.76 million shs2.59 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
-2.08%-5.08%-8.75%+0.20%-11.68%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
MannKind Corporation stock logo
MNKD
MannKind
+25.05%+41.03%+53.07%+31.95%-8.31%
Novavax, Inc. stock logo
NVAX
Novavax
+1.07%+0.67%+15.09%+5.59%-39.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
4.6179 of 5 stars
3.32.00.04.73.03.31.9
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
4.1264 of 5 stars
3.63.00.00.03.21.73.1
Novavax, Inc. stock logo
NVAX
Novavax
4.5947 of 5 stars
3.13.00.04.72.20.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.33142.97% Upside
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.0080.67% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.13
Hold$14.2991.88% Upside

Current Analyst Ratings Breakdown

Latest KERX, DVAX, MNKD, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
MannKind Corporation stock logo
MNKD
MannKind
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$9.00 ➝ $10.00
9/2/2025
MannKind Corporation stock logo
MNKD
MannKind
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $11.00
8/28/2025
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
8/26/2025
MannKind Corporation stock logo
MNKD
MannKind
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
8/25/2025
MannKind Corporation stock logo
MNKD
MannKind
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
8/22/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$32.00
8/20/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.00
8/8/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$31.00 ➝ $32.00
8/7/2025
MannKind Corporation stock logo
MNKD
MannKind
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $7.00
7/23/2025
MannKind Corporation stock logo
MNKD
MannKind
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.00
7/22/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$277.25M4.24$0.16 per share63.91$4.21 per share2.38
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$60.64M5.67N/AN/A($0.12) per share-28.00
MannKind Corporation stock logo
MNKD
MannKind
$301.74M5.63$0.17 per share33.07($0.18) per share-30.75
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.77N/AN/A$0.23 per share32.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.46N/A20.44N/A-16.67%5.10%3.00%11/6/2025 (Estimated)
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
-$163.44M-$0.88N/AN/AN/A-96.41%N/A-60.05%N/A
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1150.4124.07N/A10.87%-32.60%7.81%11/6/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.283.2793.060.1039.20%-142.33%28.65%11/11/2025 (Estimated)

Latest KERX, DVAX, MNKD, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.12$0.14+$0.02$0.14$87.55 million$95.44 million
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04$0.05+$0.01N/A$77.82 million$76.53 million
8/6/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.45
6.65
6.01
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A
2.21
1.19
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.50
2.24
Novavax, Inc. stock logo
NVAX
Novavax
5.93
2.36
2.34

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
69.00%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
1.61%
MannKind Corporation stock logo
MNKD
MannKind
3.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.27 million113.77 millionOptionable
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A102.38 millionN/AOptionable
MannKind Corporation stock logo
MNKD
MannKind
400306.83 million297.62 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990162.42 million160.80 millionOptionable

Recent News About These Companies

Novavax, Inc. (NASDAQ:NVAX) Receives $14.29 Consensus PT from Analysts
Invesco Ltd. Boosts Stake in Novavax, Inc. $NVAX
FY2025 Earnings Forecast for Novavax Issued By HC Wainwright
HC Wainwright Comments on Novavax FY2025 Earnings
Nuveen LLC Purchases New Position in Novavax, Inc. $NVAX
Q3 Earnings Forecast for Novavax Issued By HC Wainwright
HC Wainwright Initiates Coverage on Novavax (NASDAQ:NVAX)
What is HC Wainwright's Estimate for Novavax Q3 Earnings?
Novavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$10.02 +0.11 (+1.06%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Keryx Biopharmaceuticals stock logo

Keryx Biopharmaceuticals NASDAQ:KERX

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

MannKind stock logo

MannKind NASDAQ:MNKD

$5.54 -0.21 (-3.57%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.44 -0.11 (-1.39%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.